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A B S T R A C T
Objective: To predict the 3-months mortality in permanently bedridden medical non-oncologic inpatients.
Patients and Methods: 2788 consecutive patients admitted in 5 Italian Internal Medicine units from January 2016 through January 2017 were prospectively screened;
644 oncologic patients were excluded; 2144 non-oncologic patients (1021 female) were followed-up for mortality for 6 months. Main outcome was 3-months
mortality in permanently bedridden inpatients with at least 2 of: creatinine clearance< 35ml/min; albumin < 2.5 g/dl; at least 2 hospital admissions in the
previous 6 months. Advanced dementia and dysphagia were also recorded.
Results: Mean age of the 2144 patients was 73.9 (SD, 14.9) years; 374 (17%) were permanently bedridden, 435 (20%) had a creatinine clearance< 35ml/min, 217
(10%) albumin < 2,5 g/dl, 112 (5%) at least 2 hospital admissions in the previous 6 months. Seventy-seven (4%) patients were permanently bedridden with at least
2 of the above mentioned items, and 48 of them died within 3 months (62%) (p < 0.001;95% CI 51–73%). Regression coefficients of the variables associated with 3-
months mortality in multivariate analysis in 998 patients of unit 1 (training cohort) were used to create a simple score, which was validated in the 1146 patients of
the other units (validation cohort) and performed well in predicting the 3-months mortality (https://www.ejcrim.com/beclap/).
Conclusions: Approximately two out of three non-oncologic medical patients permanently bedridden having 2 of the abovementioned items are dead 3 months after
index admission; a simple score including bedridden status, creatinine clearance, albumin, dysphagia, age and sex may help discuss management priorities.
1. Introduction
Prediction of short term prognosis of medical frail patients is re-
levant to avoid unintended iatrogenic side-effects and to plan the
priorities [1-4]. Scant evidence is available to assess the risk of short-
term mortality of non-oncologic elderly frail patients and many prog-
nostic scores have been proposed [1,5].
Busy Internists need simple instruments, easy to use. Being perma-
nently bedridden indicates a severely compromised performance status
[6]; kidney failure is a major contributor to poor outcomes [7]; albumin
level is a well-known prognostic factor [8-10], and recent hospital
admissions indicate that patients’ stability is deteriorating [11].
We published an exploratory analysis [12] showing that bedridden
status, severely reduced kidney function, recent hospital admissions
and hypoalbumin were associated with high risk of three-months
mortality in non-oncologic patients after discharge from internal med-
icine and geriatric hospital wards in an Italian registry (REPOSI). That
study had some limitations: the registry was not specifically designed to
evaluate the risk of three-month mortality; moreover, follow-up at three
months was lacking for about one third of patients.
Specifically designed prospective studies with no drop-outs are
needed to further validate these data.
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Aim of the present study was to prospectively assess the 3-months
mortality in consecutive non-oncologic permanently bedridden in-
patients (BE) with at least 2 of the following variables (whose asso-
ciation with mortality is well established) [6-11]: creatinine clear-
ance<35ml/min (CL); albumin < 2.5 g/dl (A); at least 2 hospital
admissions in the previous 6 months (P) (BECLAP). Advanced dementia
(AD) and dysphagia (DY) are less clearly associated with short-term
mortality [11-16], so we recorded these items as secondary outcomes.
The second step was to assess the effect of each variable on 3-months
mortality, with the corresponding regression coefficients. The third step
was to create a prognostic score in a training cohort that was then as-
sessed in a validation cohort.
2. Methods
2.1. Study design and patients
This is a prospective cohort study performed in 5 Italian Internal
Medicine units (Bergamo, Milano, San Giovanni Bianco, Varese1 and
Varese2). Enrollment started in January 2016 and ended in January
2017; each patient was followed-up for mortality for 6 months, with no
drop-outs, and follow-up ended in July 2017. Bergamo Hospital, the
promoter center, is a big tertiary hospital; San Giovanni Bianco is a
small local hospital; Milano and Varese are university teaching hospi-
tals. The units are heterogeneous; their wide diagnosis-related groups
are showed in eTable 1: case mix indexes ranged from 0.91 to 1.39;
2788 consecutive patients admitted in the 5 units were screened
(Fig. 1). Oncologic patients (644) were excluded. 2144 non-oncologic
patients were evaluated for the following pre-specified variables: to be
in a permanent bedridden status (inability to walk or stand upright
during the whole hospital stay), creatinine clearance<35ml/min; al-
bumin < 2.5 g/dl; at least 2 hospital admissions in the previous 6
months.
The first step was to assess the mortality at three-months in patients
permanently bedridden and with at least 2 of the other conditions
(BECLAP: Bedridden, creatinine Clearance, Albumin, Previous hospital
admission). According to the pre-specified protocol only the above-
mentioned variables (BECLAP) were assessed for the main outcome, but
advanced dementia and dysphagia were also recorded to evaluate their
possible role in a predictive score. The second step was to assess the
effect of each variable on mortality at 3 months, with the corresponding
regression coefficients. The third step was to create a score based on the
variables that were statistically significant in a multivariate analysis
performed in a predefined training cohort; the score's predictivity was
then assessed in a validation cohort (1146 patients admitted in the
other 4 units).
The Ethics committees at each participating center approved the
study.
2.2. Inclusion and exclusion criteria and definitions
2788 consecutive patients admitted in the 5 units were screened
(Fig. 1). Oncologic patients (644) were excluded. A patient was con-
sidered ``oncologic'' when a malignant solid or hematological neoplasm
was present during the hospital stay or when treated with che-
motherapy or radiotherapy in the previous 6 months; patients with only
non-melanoma skin cancers were considered non-oncological in ab-
sence of metastasis.
Permanent bedridden status was defined as the inability to walk or
stand upright during the whole hospital stay. This parameter was
deemed easier to assess as compared to the use of other indexes of
performance status, such as the Barthel index, Karnofsky index, etc.
Creatinine clearance (the last value recorded during the hospital
stay) was calculated according to the Cockcroft-Gault equation since
this equation is easily available and it takes into account age, weight
and sex.
The first value of albumin (g/dl) recorded during the hospital stay
was used as therapeutic infusions of albumin may alter subsequent
measurements.
All hospital admission in the previous 6 months, urgent or planned,
in any hospital unit, either medical or surgical, were recorded.
Advanced dementia was defined as profound memory deficits (e.g.,
inability to recognize family members), minimal verbal abilities, in-
ability to ambulate independently, inability to perform any activities of
daily living, and urinary and fecal incontinence (Stage 7 on the Global
Deterioration Scale, ranging from 1 to 7, with higher stages indicating
worse dementia); in this condition Mini-mental state examination
(MMSE) cannot be administered [17].
Dysphagia was defined as the presence of evident difficulty in oral
feeding; positioning of a nasogastric tube of percutaneous endoscopic
Fig. 1. Flow chart of the study.
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gastrostomy (PEG) was recorded [14].
2.2.1. Follow up, outcomes and measures
Main outcome was 3-months mortality in non-oncological perma-
nently bedridden patients (BE) and with at least 2 of: CL, A and P.
Mortality data were provided by the Cause of Death Registry
(managed by Regional Health Authority), without lost to follow-up.
Secondary outcomes were: the effects of CL, A and P, plus also ad-
vanced dementia (AD) and dysphagia (DY), on mortality at 3 and 6
months, and the elaboration of a score able to predict 3-months mor-
tality in medical non-oncologic patients; 998 patients in the unit 1
(Bergamo) were the derivation cohort and 1146 patients in the other
units were the validation cohort
2.3. Sample size and statistical analysis
Required sample size was estimated considering the effect of a
single covariate on survival under Cox proportional hazards model,
assuming hypothesis testing is performed by two-tailed Wald's test on
the coefficients estimated by partial likelihood.
The expected risk model includes the effect of more non-in-
dependent covariates, therefore a degree of multiple correlation was
assumed (R2= 0.50).
In a previous 2011 unpublished analysis performed on 300 con-
secutive patients in unit 1, observed 3-months mortality was ≈12–15%.
Assuming a conservative 10% estimate and a low effect size (regression
coefficient= 0.8), about 1000 patients would be needed to achieve
80% power under an alpha Type I error of 5%.
Categorical variables and mortality are presented as absolute and
relative frequencies (percentages). A summary of mortality is presented
stratified for each risk factor and for combined classes of risk.
Quantitative variables are summarized and presented as
Mean ± Standard Deviation. The effect of single categorical variables
on survival at three and six months was assessed in univariate analyses
by plotting the Kaplan-Meier survival curves stratified by the variable
of interest and performing the log-rank test. Multivariate analyses on
survival were performed using Cox proportional hazards models, and
the effect of the single variables on the outcome was assessed by two
tailed Wald's tests on the coefficients.
Coefficients estimated in the predefined training cohort (998 pa-
tients admitted in unit 1) from the Cox model were used for production
of a prognostic score which was then validated by plotting the Receiver
Operating Characteristic (ROC) curve and computing the corresponding
Area Under Curve (AUC). For calibration, we ran logistic regression of
mortality on the score in the training set and then ran the Hosmer-
Lemeshow test with ten quantiles on the validation set, considering a
non-significant p-value as evidence of good calibration.
P-values below 0.05 were considered significant in all the analyses.
The entire analysis was performed on Stata, version 13.
3. Results
2788 consecutive patients admitted in the 5 Italian Internal
Medicine units were screened; 644 oncologic patients were excluded;
2144 non-oncologic patients were analyzed (1021 female) (Fig.1).
Baseline features are described in Table 1.
3.1. Main outcome
Three-hundreds seventy-four (17%) patients were permanently
bedridden, 435 (20%) had a creatinine clearance< 35ml/min, 217
(10%) albumin <2.5 g/dl and 112 (5%) at least 2 any hospital ad-
missions in the previous 6 months. Seventy-seven patients (4%) sa-
tisfied the predefined ``condition'': BE with at least 2 of: CL; A and P; 48
of them died within 3 months from index admission (62%) (p < 0.001
Condition vs. no Condition; 95% CI 51–73%). Fig.2 reports the Kaplan-
Meier survival curves at 3 months for the condition (main outcome).
Two Cox regression models including also effects of age, sex, and center
were estimated and the Wald test on the coefficients confirmed the
highly significant effect of the Condition on survival at three months
(HR=5.62, p < 0.001).
3.2. Secondary outcomes
3.2.1. Effects of single parameters on 3-months mortality
Table 2 describes the observed 3-months mortality for each separate
combination of variables: just 1 variable; 2 coexisting variables; 3 co-
existing variables.
Log-rank tests were highly significant for each variable (p < 0.01 o
p < 0.001) (see Fig.3). Thus, we ran a multivariate analysis in order to
confirm the predictivity of these parameters using a Cox proportional
hazards model including the variables mentioned above (model 1,
eTable 2). For greater accuracy, in this analysis albumin and creatinine
clearance where dealt with as continuous variables. The model included
age, sex and center as adjusting factors. Bedridden status, creatinine
clearance, albumin, (p < 0.001) and dysphagia (p < 0.01) were
highly associated with 3-months mortality in the multivariate analysis;
at least 2 hospital admissions in the previous 6 months had a borderline
statistical significance (p=0.062), while advanced dementia was not
significantly associated (eTable 2). The center effect on mortality was
significant (P=0.007), probably related to the different case mix in-
dexes of the units (see eTable 1).
Fig. 3 reports the Kaplan-Meier survival curves at 3 (and 6) months
stratified for each significant variable: BE, CL, A, DY.
3.2.2. Prognostic score
As per pre-definite protocol, we then re-calculated the regression
coefficients of the variables of interest, plus age and sex, in a new model
(model 2) fitted in the derivation subset of the 998 patients of unit 1
(Bergamo), to create a score predictive of the probability of death at 3
months (eTable 2). The regression coefficients associated to each sig-
nificant variable (plus age and sex) were multiplied×10 and used to
assign a prognostic score according to the following formula (supple-
mentary excel calculator):= × + ×× ++ +
Score Age if male Albumin
Creatinine Clearance if bedridden
if dysphagic
0.1 3.6( ) 8.2
0.2 14.3( )
6.9 ( ) 50
The score includes an arbitrary constant of 50 used to avoid
Table 1
baseline features of non-oncologic patients, with overall 3-months mortality.
N (%) Tot= 2144
Age (years)
Mean ± SD 73.9 ± 14.9
Median (IQR) 78.0 (67.0, 85.0)
Sex
Female 1021 (47.6%)
Male 1124 (52.4%)
Creatinine Clearance < 35ml/min 435 (20.3%)
Mean ± SD 63.2 ± 33.9
Median (IQR) 57.0 (38.8, 82.3)
Albumin < 2.5 g/dL 217 (10.1%)
Mean ± SD 3.2 ± 0.5
Median (IQR) 3.2 (2.8, 3.6)
Permanently bedridden 374 (17.4%)
At least 2 admissions in the previous 6
months
112 (5.0%)
Advanced Dementia 313 (14.6%)
Dysphagia 224 (10.5%)
Overall 3-months mortality 306 (14%)
Of whom 127 during the index
admission
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returning negative scores. We had no lost to follow-up at 3 months so
we were also able to perform a logistic regression of 3-months mortality
on the score (OR=1.13, 1.10–1.15).
The curve describing the increment of the probability of death at 3
months predicted by the logistic model as a function of score is reported
in Fig 1-online-only. Scores and the corresponding risks for some re-
levant values are reported in eTable 3.
The score was then validated in the validation cohort: 1146 patients
of the other 4 units; its predictivity was assessed plotting the corre-
sponding ROC curve (Fig. 2-online-only). The area under the curve was
0.82, indicating a very good predictivity of the score. Hosmer-Leme-
show Chi2 was 13.82 with p=0.181, confirming that predicted and
expected mortality do not differ significantly in the validation set. The
corresponding calibration plot of predicted vs. observed mortality is
shown in Fig.3-online only.
An excel file to calculate the score with corresponding probabilities
of death at 3 months is available as supplementary material, and a
calculator is freely available at https://www.ejcrim.com/beclap/.
3.2.3. 6-month mortality
Fig. 3 shows the Kaplan-Meier survival curves also at 6 months
(with the log-rank tests) for the condition studied and for each single
variable; eTable 4 is a matrix reporting observed 6-months mortality for
each separate combination of variables. Of note 56/77 (73%) patients
fulfilling the predefined condition were dead at 6 months (Fig. 2) and
several combinations of variables showed strikingly elevated mortality
(see eTable 4).
Log-rank tests were highly significant for each variable (< 0.001)
(see Fig.2) (univariate analysis), and all the variables, including de-
mentia, were statistically associated with 6-months mortality.
4. Discussion
Prognosis has a central role in clinical decision-making [2], but
most studies address medium-long term prognosis, e.g. mortality at 1
year [1]. Still what is crucial in clinical decisions is short-term prog-
nosis, i.e. 3-months mortality, that was not addressed as primary out-
come in prognostic studies [1,2,18,19]. Indeed, life expectancy of three
months is now deemed a condition in which palliative care should be
considered [3,16,20], activating protocols that have been associated
with a better quality of life but also prolonged survival in patients with
advanced cancers [21], probably due to fewer iatrogenic side effects in
fragile patients; it is not known whether this is true for non-oncologic
patients [16,22].
In this prospective observational study 2144 consecutive non-on-
cologic inpatients admitted in Italian units of internal Medicine were
analyzed: only 77 were permanently bedridden during the entire hos-
pital stay and had at least 2 of CL, A, P; 48 of them were dead 3 months
after index admission (62%). Many more patients showed different
combinations of variables (see Fig. 1, Table 2 and eTable 4). In these
patients clinical decisions are often difficult, also for uncertainty re-
garding short-term prognosis; a simple score (BECLAP-D Score) was
then calculated in a derivation cohort and validated in a validation
cohort, to help discuss management priorities in these frail patients.
Table 2
Matrix describing in detail the observed 3-months mortality for each separate combination of variables: just 1 variable; 2 coexisting variables; 3 coexisting variables.
3-months observed mortality by combination of parametersa
All patients (2144)
BE A CL AD P DY
BE 163/374 (43.6%)
A 51/98 (52.0%) 78/217 (35.9%)
CL 64/102 (62.7%) 23/48 (47.9%) 126/435 (29.0%)
AD 111/232 (47.8%) 39/70 (55.7%) 48/89 (53.9%) 131/313 (41.9%)
P 22/39 (56.4%) 15/29 (51.7%) 15/32 (46.9%) 21/33 (63.6%) 35/112 (31.3%)
DY 84/170 (49.4%) 31/51 (60.8%) 37/55 (67.3%) 77/155 (49.7%) 13/23 (56.5%) 96/224 (42.9%)
Bedridden only (374)
A CL AD P DY
A 51/98 (52.0%)
CL 15/25 (60.0%) 64/102 (62.7%)
AD 33/59 (55.9%) 40/61 (65.6%) 111/232 (47.8%)
P 11/17 (64.7%) 11/14 (78.6%) 17/26 (65.4%) 22/39 (56.4%)
DY 27/46 (58.7%) 32/42 (76.2%) 70/137 (51.1%) 12/17 (70.6%) 84/170 (49.4%)
a BE: Permanently Bedridden; CL: Creatinine Clearance<35mL/min; A: Albumin < 2.5 g/dL; P: two or more hospital admissions in the previous six months; AD:
Advanced Dementia; DY: Dysphagia.
Fig. 2. Kaplan-Meier survival curves at 3 at 6 months (with the log-rank tests) for the condition studied (main outcome): permanently bedridden plus at least 2 of
creatinine clearance< 35ml/min, albumin <2.5 g/dl and at least 2 hospital admissions in the previous 6 months.
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The score also includes dysphagia and is available on line (web ad-
denda).
Overall, we selected items that are easily assessed in a clinical
context but also prognostically relevant according to our recent ex-
ploratory analysis [12] and to previously published studies [6-11].
Being permanently bedridden obviously indicates a severely compro-
mised performance status [6], and it is a very simple parameter to as-
sess, while the Bartel index is not routinely adopted in the internal
medicine wards, because it is time consuming.
Low albumin levels are a predictor of poor prognosis [8], are as-
sociated with in-hospital mortality [9], may reflect malnutrition, but
are also a potential marker of diseases, such as cirrhosis and heart or
kidney failure [9,10]. Recent hospital admissions may indicate that the
relative stability of the fragile patients is deteriorating [11]. Finally, the
possible impact on short term mortality of dementia and dysphagia, an
emerging issue in medical elderly patients, is less well established [13-
17], and for this reason we collected these variables just as secondary
outcomes.
Many studies addressed the prognosis of medical non-oncologic
patients, and scores have been developed [2,15] but there are some
caveats. Firstly, several scores are disease-specific [15], i.e. for heart
[23], liver [24] or kidney failure [25], but many fragile medical non
oncologic patients have coexisting conditions, including geriatric syn-
dromes [4,26,27].
Secondly, most scores appear too complex for routine clinical use
[19,28-31].
Thirdly, many scores predict mortality at medium-long term, i.e. at
12 months, a time window that is less relevant for clinical decision-
making [19,28,30-42]. Other studies addressed 6-months mortality
[8,43], and often for specific diseases such as heart failure, dementia,
cirrhosis [15]. Three-months mortality was evaluated in 2 studies
[18,19]: in the first study it was evaluated together with other less hard
outcomes, such as functional decline and high-healthcare demand [18].
In the second study Sancarlo [19] validated a Multidimensional Prog-
nostic Index for 1-year mortality initially proposed by Pilotto [31],
addressing also mortality at 1 and 3 months, and simplifying it, but that
index was still based on a total of 51 items in 8 domains of the com-
prehensive geriatric assessment, making it difficult to apply in clinical
practice.
Many of these indices rely on administrative datasets [32,44], and
the accuracy of ICD-9 codes has been called into question [2].
Finally, most studies included oncologic patients [19,28,31,44].
Compared to most of these scores, our instrument is based on items
that are more easily assessed in a clinical context, and we think that
short term prognosis, i.e. 3-months mortality, is more relevant to clin-
ical decision-making.
There are no widely accepted validation criteria for discrimination
and calibration of prognostic indices [1]. On our part, we found an AUC
(c-statistic) of 0.82, and we tested calibration using Hosmer-Lemeshow
test, which confirmed that predicted and expected mortality do not
differ significantly in the validation set. All points of the calibration plot
laid close to the bisector (Fig.3-online only). Notably, our score per-
formed well even in presence of differences in case mix indexes be-
tween centers.
Further study will be needed to accurately assess the short-term
prognosis in non-oncologic inpatients, and to evaluate whether the
early activation of palliative care in active care (``simultaneous care'')
[3,16,45] will improve the quality and duration of life in non-oncologic
medical inpatients with limited life expectancy.
Fig. 3. Kaplan-Meier survival curves at 3 at 6 months (with the log-rank tests) for each single variable: to be permanently bedridden, albumin < 2,5 g/dl, creatinine
clearance<35ml/min and dysphagia.
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5. Limitations
Our study has several limitations. First, it is a national (Italian)
study and, therefore, BECLAP-D score should be validated in patients
from other countries. However, the main characteristics of the
``modern'' non-oncologic medical inpatient are becoming similar in
most industrialized countries. Second, the score should be validated by
investigators not involved in its elaboration to become widely accepted.
On the other hand, a strength of our study is the absence of drop-out for
the main outcome (mortality).
6. Conclusions
Short-term prognosis, i.e. 3-months mortality, is rarely addressed in
clinical studies, still it is of extreme relevance. This prospective ob-
servational study analyzed 2144 medical non-oncologic inpatients; of
them 77 were permanently bedridden (unable to walk or stand upright
during the whole hospital stay) and had at least 2 of: creatinine clear-
ance<35ml/min; albumin < 2.5 g/dl; at least 2 hospital admissions
in the previous 6 months: approximately 2 out of 3 of these patients
(62%) were dead 3 months after index admission. A simple score
(BECLAP-D Score), including these variables plus dysphagia, was ac-
curate in predicting early mortality in frail medical non-oncologic pa-
tients, and may help physicians to identify management priorities and
avoid therapeutic obstinacy.
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